Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 9/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404860 | 0.80 | PTPN1 (0.51) | PTPN5PTPN1NR1H2PTPN2NR1H3 | |
| SCHEMBL7193463 | 0.79 | PTPN1 (0.46) | PTPN5PTPN1NR1H2NR1H3RXRA | |
| SCHEMBL7193465 | 0.78 | PTPN1 (0.67) | PTPN5PTPN1NR1H2PTPN2NR1H3 | |
| SCHEMBL7592238 | 0.69 | PTPN1 (0.74) | PTPN5PTPN1PTPN2 | |
| SCHEMBL7188783 | 0.69 | PTPN1 (0.74) | PTPN5PTPN1PTPN2 | |
| SCHEMBL7200461 | 0.69 | NR1H2 (0.38) | PTPN5PTPN1NR1H2NR1H3RXRA | |
| SCHEMBL3740561 | 0.69 | PTPN1 (0.44) | PTPN1PTPN2 | |
| SCHEMBL7188773 | 0.69 | PTPN1 (0.73) | PTPN5PTPN1PTPN2 | |
| SCHEMBL4865776 | 0.69 | PTPN5 (0.53) | PTPN5PTPN1PTPN2 | |
| SCHEMBL7200463 | 0.69 | PTPN1 (0.52) | PTPN1NR1H2NR1H3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163932-B2 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA & CO. (CA) | 2007-01-16 | — | — | US | disclosed |
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA LTD. (CA) | 2004-09-09 | — | — | US | disclosed |
| WO-2002102813-A1 | ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS FOR TREATMENT OF DIABETES | MERCK FROSST CANADA & CO. (CA) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | PTPRF, PTPRO, PTP4A1 | PTPN5 23/4885PTPN1 16/4885CTSL 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.